Navigation Links
Beckman Coulter's Board of Directors Recommends Stockholders Accept Danaher's Cash Tender Offer
Date:2/15/2011

ORANGE COUNTY, Calif., Feb. 15, 2011 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that its board of directors unanimously recommends that Beckman Coulter's stockholders tender their shares to Danaher Corporation (NYSE: DHR) at the previously announced price of $83.50 per share of Beckman Coulter's common stock.

(Logo:  http://photos.prnewswire.com/prnh/20031202/BECLOGO)

The transaction is expected to close during the first half of 2011 and is subject to various conditions, including the tender of at least a majority of the outstanding shares, calculated on a fully-diluted basis, of Beckman Coulter's common stock in the tender offer and the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other applicable regulatory approvals. Following completion of the tender offer, Danaher will acquire all remaining shares of Beckman Coulter's common stock through a second step merger at the same price per share paid in the tender offer (without interest and subject to applicable withholding taxes).

In consultation with its independent financial and legal advisors, Beckman Coulter has filed a solicitation/recommendation statement on Schedule 14D-9 with the Securities and Exchange Commission. Stockholders of Beckman Coulter are advised to read Beckman Coulter's Schedule 14D-9 statement because it contains important information. Stockholders may obtain a free copy of the statement at the SEC's website at www.sec.gov. Stockholders may also obtain, without charge, a copy of the statement from Beckman Coulter by telephone at (714) 961-6320, by mail at Beckman Coulter, Inc., Investor Relations, 250 S. Kraemer Blvd, Brea, California 92822, or by going to Beckman Coulter's Investor Relations page on its corporate web site at www.beckmancoulter.com.

Goldman, Sachs & Co. is serving as financial advisor, and Latham & Watkins LLP is serving as legal counsel, to Beckman Coulter.

About Beckman Coulter Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represent about 80% of the company's 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com.

Note on Forward-Looking Statements Certain statements either contained in or incorporated by reference into this document are "forward-looking statements" including, but not limited to, statements regarding the combined companies' plans following, and the expected completion of, the proposed acquisition. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements and generally include statements that are predictive in nature and depend upon or refer to future events or conditions. Risks and uncertainties include the ability of Beckman Coulter and Danaher to complete the transactions contemplated in the merger agreement, including the parties' abilities to satisfy the conditions to the consummation of the proposed acquisition; the possibility of any termination of the merger agreement; the timing of the tender offer and the subsequent merger; uncertainties as to how many of Beckman Coulter's stockholders will tender their shares of common stock in the tender offer; the possibility that various other conditions to the consummation of the tender offer or the subsequent merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the acquisition; other uncertainties pertaining to the business of Beckman Coulter or Danaher; product safety; legislative and regulatory activity and oversight; the continuing global economic uncertainty and other risks detailed in (i) Beckman Coulter's public filings with the SEC from time to time, including Beckman Coulter's most recent Annual Report on Form 10-K for the year ended December 31, 2009, Quarterly Reports on Form 10-Q and its subsequently filed SEC reports, each as filed with the SEC, and (ii) Danaher's public filings with the SEC from time to time, including Danaher's most recent Annual Report on Form 10-K for the year ended December 31, 2009, Quarterly Reports on Form 10-Q and its subsequently filed SEC reports, each as filed with the SEC, in each case, which contains and identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements. The reader is cautioned not to unduly rely on these forward-looking statements. Beckman Coulter expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law. Contact:

Cynthia Skoglund

(714) 961-6320Investor Relations
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Beckman Coulter Announces Third Quarter 2009 Results
5. Beckman Coulter Announces Conference Call and Webcast of Accompanying Slides in Conjunction With Third Quarter 2009 Earnings
6. Beckman Coulter Affirms 2009 Outlook
7. Beckman Coulter to Present at the 2009 Piper Jaffray Healthcare Conference
8. Beckman Coulter to Present at Upcoming Healthcare Conferences
9. Beckman Coulter to Present at the Piper Jaffray 22nd Annual Unplugged Health Care Conference
10. Danaher to Acquire Beckman Coulter, Inc.
11. Beckman Coulter Declares Quarterly Dividend Payout of $0.19 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... 2016 first quarter ended December 31, 2015. ... First Quarter Highlights , Revenue of $36.5 million ... 2015 , Domestic Radiation Measurement services revenues increased 2.8% ...
(Date:2/9/2016)... , February 9, 2016 ... gab heute den Abschluss eines Kooperationsvertrags mit ... umfassender Lösungen in den Bereichen Next-Generation-Sequencing (NGS), ... QGEN ; Frankfurt Prime Standard: QIA) gab ... Genomics für die Entwicklung und Förderung umfassender ...
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... disease and heart failure, today announced that it intends to ... stock in an underwritten public offering.  The offering is subject ... assurance as to whether or when the offering may be ... the offering.   --> --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... It’s that time of year when most people have forgotten all about their New ... (IAAM), Hall of Fame athlete and Garrison Forest School athletic director since 2005, knows ... of her first decisions when her IAAM two-year presidency began last July was to ...
(Date:2/9/2016)... Albuquerque, NM (PRWEB) , ... February 09, 2016 , ... ... proceeds from its Heart Rate Variability scans throughout the month to the American Heart ... to spot the first signs of heart disease and Health Quest’s INSiGHT Pulse Wave ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... Snowfall4pod Digital, creators of the gContentManager & Distribution Network, today announced the ... and print-on-demand network. , AVALANCHE allows enterprise customers to license and create ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research ... playing field .” , As corresponding author Dr John F. Peppin says “Terminology matters, ... diagnose our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are ...
(Date:2/9/2016)... ... 2016 , ... METTLER TOLEDO has published a new guide ... understanding of the techniques they use so they can more easily spot potential ... and rework to create a leaner overall lab experience. , The new ...
Breaking Medicine News(10 mins):